Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Synergistic neurotrophic effects of piracetam and thiotriazoline

https://doi.org/10.14412/2074-2711-2016-1-86-89

Full Text:

Abstract

The paper considers the synergy between the nootropic drug piracetam and the metabolic agent thiotriazoline that maintains energy metabolism and survival of neurons and other types of cells. Piracetam, a nootropic drug, a chemical pyrrolidone derivative, is used in neurological, psychiatric, and narcological practice. There is evidence on the positive effect of piracetam in elderly and senile patients with coronary heart disease. This drug is supposed to stimulate redox processes, to enhance glucose utilization, and to improve regional blood flow in the ischemic brain regions. Due to its action, the drug activates glycolytic processes and elevates ATP concentrations in brain tissue. Thiotriazoline is a compound that has antioxidant, anti-ischemic properties. The co-administration of piracetam and thiothriazoline is an innovation area in the treatment of stroke and other brain damages, especially in insulin resistance and high blood glucose levels. The paper considers the neurobiological properties of thiotriazoline and piracetam, which synergistically exert neuroprotective and neurotrophic effects.

About the Authors

O. A. Gromova
Ivanovo State Medical Academy, Ministry of Health of Russia, Ivanovo, Russia 8, Sheremetevsky Passage., Ivanovo 153000 Russian Satellite Neurobiology Center, Trace Element Institute for UNESCO, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia 1, Ostrovityanov St., Moscow 117997
Russian Federation


I. Yu. Torshin
Russian Satellite Neurobiology Center, Trace Element Institute for UNESCO, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia 1, Ostrovityanov St., Moscow 117997
Russian Federation


A. V. Pronin
Ivanovo State Medical Academy, Ministry of Health of Russia, Ivanovo, Russia 8, Sheremetevsky Passage., Ivanovo 153000 Russian Satellite Neurobiology Center, Trace Element Institute for UNESCO, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia 1, Ostrovityanov St., Moscow 117997
Russian Federation


A. Yu. Volkov
Russian Satellite Neurobiology Center, Trace Element Institute for UNESCO, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia 1, Ostrovityanov St., Moscow 117997
Russian Federation


References

1. Машковский МД. Лекарственные средства. 19-е изд. Москва: Новая волна; 2015. С. 111-5. [Mashkovskii MD. Lekarstvennye sredstva [Medications]. 19th ed. Moscow: Novaya volna; 2015. P. 111-5.]

2. Воронина ТА, Серединин СБ. Ноотропные препараты, достижение и новые проблемы. Экспериментальная и клиническая фармакология. 1998;61(4):3-9. [Voronina TA, Seredinin SB. Nootropics, achievement and new challenges. Eksperimental'naya i klinicheskaya farmakologiya. 1998;61(4):3-9. (In Russ.)].

3. Tomlinson DR. Future prevention and treatment of diabetic neuropathy. Diabetes Metab. 1998 Nov;24 Suppl 3:79-83.

4. Tuglu D, Yuvanc E, Ozan T, Bal F, et al. Protective effects of udenafil citrate, piracetam and dexmedetomidine treatment on testicular torsion/detorsion-induced ischaemia/reperfusion injury in rats. Andrologia. 2015 Nov 20. doi: 10.1111/and.12499. [Epub ahead of print].

5. Kovalev GI, Kondrakhin EA, Salimov RM, Neznamov GG. The influence of piracetam on behavior and brain receptors in C57BL/6 and BALB/c mice: nootropic and anxiolytic effects. Eksp Klin Farmakol. 2013;76(9):3-10.

6. Fang Y, Qiu Z, Hu W, et al. Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: A meta-analysis. Exp Ther Med. 2014 Feb;7(2):429-34. Epub 2013 Nov 26.

7. Stockburger C, Kurz C, Koch KA, et al. Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam. Biochem Soc Trans. 2013 Oct;41(5):1331-4. doi: 10.1042/BST20130054.

8. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3): 181-94.

9. Firstova IuIu, Dolotov OV, Kondrakhin EA, et al. Effects of nootropic drugs on hippocampal and cortical BDNF levels in mice with different exploratory behavior efficacy. Eksp Klin Farmakol. 2009 Nov-Dec;72(6):3-6.

10. Cardile V, Pavone A, Gulino R, et al. Expression of brain-derived neurotrophic factor (BDNF) and inducible nitric oxide synthase (iNOS) in rat astrocyte cultures treated with Levetiracetam. Brain Res. 2003 Jun 27;976(2):227-33.

11. Gao L, Peng X, Huo S, et al. Acteoside enhances expression of neurotrophin-3 in brain tissues of subacute aging mice induced by D-galactose combined with aluminum trichloride. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Oct;30(10):1022-5.

12. Козловский ВИ, Коневалова НЮ, Козловская СП. Новый цитопротектор тиотриазолин. Вестник фармации. 2007;34(4):55-9. [Kozlovskii VI, Konevalova NYu, Kozlovskaya SP. New cytoprotector thiotriazolin. Vestnik farmatsii. 2007;34(4):55-9. (In Russ.)].

13. Дунаев ВВ, Крайдашенко ОВ, Красько НП и др. Тиотриазолин в терапии ишемической болезни сердца. Рецепт. 2007;54(4):81-3. [Dunaev VV, Kraidashenko OV, Kras'ko NP, et al. Thiotriazolin in the treatment of coronary heart disease. Retsept. 2007;54(4):81-3. (In Russ.)].

14. Манищенкова ЮА, Шкала ЛВ, Дудич ТИ и др. Оксидантный стресс у больных с сахарным диабетом 2-го типа, сочетанным с обострением хронического пиелонефрита. Международный эндокринологический журнал. 2013;51(3):19-22. [Manishchenkova YuA, Shkala LV, Dudich TI, et al. Oxidative stress in patients with diabetes mellitus of the 2nd type, associated with exacerbation of chronic pyelonephritis. Mezhdunarodnyi endokrinologicheskii zhurnal. 2013;51(3):19-22. (In Russ.)].

15. Шишкова ВН. Основные патогенетические механизмы развития ишемических повреждений и возможность их коррекции у пациентов с сочетанной сердечно-сосудистой патологией. Фарматека. 2015;(13):64-9. [Shishkova VN. The main pathogenetic mechanisms of development of ischemic damage and the possibility of their correction in patients with concomitant cardiovascular pathology. Farmateka. 2015;(13):64-9. (In Russ.)].

16. Карабут ЛВ. Применение тиотриазолина в неврологической практике. Проблеми екологiчної та медичної генетики i клiнiчної iмунологiї. 2011;(5):341-7. [Karabut LV. The use of thiotriazolin in neurological practice. Problemi ekologіchnoї ta medichnoї genetiki і klіnіchnoї іmunologії. 2011;(5):341-7. (In Russ.)].

17. Савченко МА, Ярмолович ВВ, Власенкова ЕС, Борис МА. Применение тиотриазолина в амбулаторной практике: опыт и перспективы. Медицинские новости. 2013;(9):69-74. [Savchenko MA, Yarmolovich VV, Vlasenkova ES, Boris MA. The use of thiotriazolin in outpatient facilities: experience and prospects. Meditsinskie novosti. 2013;(9):69-74. (In Russ.)].

18. Ушаков АВ, Гагарина АА. Эффективность метаболической терапии в лечении пациентов с сердечной недостаточностью на фоне сахарного диабета. Кардиология и сердечно-сосудистая хирургия. 2015;8(3): 28-32. [Ushakov AV, Gagarina AA. Efficiency of metabolic therapy in treatment of patients with heart failure on the background of diabetes mellitus. Kardiologiya i serdechno-sosudistaya khirurgiya. 2015;8(3):28-32. (In Russ.)].

19. Аль СС. Положительное действие инстилляций тиотриазолина на состояние хрусталика в условях экспериментальной световой катаракты. Проблеми екологiчної та медичної генетики i клiнiчної. 2009;(6):307- 15. [Al' SS. The positive effect of instillation of thiotriazolin on the condition of the lens in experimental cataract light conditions. Problemi ekologіchnoї ta medichnoї genetiki і klіnіchnoї. 2009;(6):307-15. (In Russ.)].

20. Беленичев ИФ, Сидорова ИВ, Дунаев ВВ и др. Фармакологическая нейропротекция постинсультных повреждений нейронов сенсомоторной зоны фронтальной коры и гиппокампа у крыс. Экспериментальная и клиническая фармакология. 2006;69(5):11-5. [Belenichev IF, Sidorova IV, Dunaev VV, et al. Pharmacological neuroprotection of post-stroke damage of neurons in the sensorimotor areas of the frontal cortex and hippocampus in rats. Eksperimental'naya i klinicheskaya farmakologiya. 2006;69(5):11-5. (In Russ.)].

21. Мазур ИА, Стец ВР, Волошин НА и др. Церебропротекторное и ноотропное лекарственное средство в таблетках, покрытых оболочкой. Патент на изобретение РФ № 2248203 от 14.02.2003. [Mazur IA, Stets VR, Voloshin NA, et al. Cerebroprotective and nootropic drug in the coated tablets. The patent for invention of the Russian Federation № 2248203. 14.02.2003.]

22. Тиоцетам (Tiocetam), инструкция по применению, противопоказания, состав [Tiocetam, instructions for use, contraindications, composition]. http://www.rlsnet.ru/tn_index_id_50956.htm


For citation:


Gromova O.A., Torshin I.Yu., Pronin A.V., Volkov A.Yu. Synergistic neurotrophic effects of piracetam and thiotriazoline. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(1):86-89. (In Russ.) https://doi.org/10.14412/2074-2711-2016-1-86-89

Views: 675


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)